Drug name - Saxenda
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6268343 | NOVO | Derivatives of GLP-1 analogs |
Aug, 2022
(a month ago) | |
| CN1951965A | NOVO | Glp-1 Derivatives |
Aug, 2017
(5 years ago) | |
| CN100569798C | NOVO | Glp-1 Derivatives |
Aug, 2017
(5 years ago) | |
| CN1740198A | NOVO | Glp-1 Derivatives |
Aug, 2017
(5 years ago) | |
| CN1232470A | NOVO | Glp-1 Derivatives |
Aug, 2017
(5 years ago) | |
| CN1271086C | NOVO | Glp-1 Derivatives |
Aug, 2017
(5 years ago) | |
| CN1951965B | NOVO | Glp-1 Derivatives |
Aug, 2017
(5 years ago) | |
| EP1056775B1 | NOVO | Glp-1 Derivatives Of Glp-1 And Exendin With Protracted Profile Of Action |
Feb, 2019
(3 years ago) | |
| EP1840134B1 | NOVO | Glp-1 Derivatives |
Feb, 2019
(3 years ago) | |
| EP1056775A1 | NOVO | Glp-1 Derivatives Of Glp-1 And Exendin With Protracted Profile Of Action |
Feb, 2019
(3 years ago) | |
| EP1840134A3 | NOVO | Glp-1 Derivatives |
Feb, 2019
(3 years ago) | |
| EP1840134A2 | NOVO | Glp-1 Derivatives |
Feb, 2019
(3 years ago) | |
| EP1060191B1 | NOVO | Derivatives Of Glp-1 Analogs |
Feb, 2019
(3 years ago) | |
| EP1062240A1 | NOVO | N-Terminally Modified Glp-1 Derivatives |
Feb, 2019
(3 years ago) | |
| EP1061946B1 | NOVO | Glp-1 Derivatives With Helix-Content Exceeding 25 %, Forming Partially Structured Micellar-Like Aggregates |
Feb, 2019
(3 years ago) | |
| EP1062240B1 | NOVO | N-Terminally Modified Glp-1 Derivatives |
Feb, 2019
(3 years ago) | |
| EP1061946A1 | NOVO | Glp-1 Derivatives With Helix-Content Exceeding 25 %, Forming Partially Structured Micellar-Like Aggregates |
Feb, 2019
(3 years ago) | |
| EP1060191A1 | NOVO | Derivatives Of Glp-1 Analogs |
Feb, 2019
(3 years ago) | |
| EP1061947B1 | NOVO | Stabilized Aqueous Glucagon Solutions Comprising Detergents |
Mar, 2019
(3 years ago) | |
| EP1061947A1 | NOVO | Stabilized Aqueous Glucagon Solutions Comprising Detergents |
Mar, 2019
(3 years ago) | |
| EP944648B1 | NOVO | Glp-1 Derivatives |
Aug, 2022
(a month ago) | |
| EP944648A1 | NOVO | Glp-1 Derivatives |
Aug, 2022
(a month ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8846618
(Pediatric) | NOVO | Stable formulation of modified GLP-1 |
Dec, 2022
(2 months from now) | |
|
US6268343
(Pediatric) | NOVO | Derivatives of GLP-1 analogs |
Feb, 2023
(4 months from now) | |
| US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(8 months from now) | |
|
US8579869
(Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Dec, 2023
(1 year, 2 months from now) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 months from now) | |
|
US7762994
(Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(2 years from now) | |
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(2 years from now) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(3 years from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(3 years from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(3 years from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(3 years from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(3 years from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(3 years from now) | |
|
US8114833
(Pediatric) | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Feb, 2026
(3 years from now) | |
|
US8684969
(Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Apr, 2026
(3 years from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(3 years from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(3 years from now) | |
| US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(3 years from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(3 years from now) | |
|
US9861757
(Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Jul, 2026
(3 years from now) | |
|
US9616180
(Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(3 years from now) | |
|
US9108002
(Pediatric) | NOVO | Automatic injection device with a top release mechanism |
Jul, 2026
(3 years from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(3 years from now) | |
|
US10220155
(Pediatric) | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jan, 2027
(4 years from now) | |
|
US8920383
(Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(4 years from now) | |
|
US9775953
(Pediatric) | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jan, 2027
(4 years from now) | |
|
USRE46363
(Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2027
(4 years from now) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(4 years from now) | |
|
US9687611
(Pediatric) | NOVO | Injection device with torsion spring and rotatable display |
Aug, 2027
(4 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(4 years from now) | |
|
US9457154
(Pediatric) | NOVO | Injection device with an end of dose feedback mechanism |
Mar, 2028
(5 years from now) | |
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(9 years from now) | |
|
US9132239
(Pediatric) | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2032
(9 years from now) | |
| US9968659 | NOVO | Liraglutide in cardiovascular conditions |
Jan, 2037
(14 years from now) | |
|
US9968659
(Pediatric) | NOVO | Liraglutide in cardiovascular conditions |
Jul, 2037
(14 years from now) | |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease
Dosage: SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 18MG/3ML (6MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.